{'fraction_non_alphanumeric': 0.021768707482993196, 'fraction_numerical': 0.013605442176870748, 'mean_word_length': 5.873831775700935, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Pathogenetics Prostate Tissue Relational Database

To effectively validate large numbers of potential prostate cancer biomarker targets, assessment of gene and protein expression coupled with tissue morphology and clinical information is necessary. These clinical studies rely not only on the tissue and experimental results but also how they are viewed and manipulated. Large numbers and diversity of clinical prostate tissue samples needed for these studies demanded the development of a database (DB) model for integrating and managing clinical, diagnostic and pathology data; tissue block data; molecular data; high density digital histologic images; protocols; and computer‐based hisotopathological scoring of tissues. The DB houses relational data from > 200 prostate cancer patients and > 500 prostate whole‐mount and biopsy tissue blocks from the NCI Prostate Molecular Profiling Program dating back to 1998. Of the whole‐mounts tissue blocks, 18 contain high‐grade adenocarcinoma, 82 contain moderate‐grade adenocarcinoma, 4 contain low‐grade adenocarcinoma, and 61 contain high‐grade PIN. Collaborative projects with specific tissues and objectives are also included within the DB, including 271 androgen independent prostate tissue biopsies. To date, seven downstream molecular analysis studies have been completed using DB data. This tissue repository DB provides a unique resource and is ideal for the research team locally and at remote locations.